The global Interleukin Inhibitors Market is estimated to be valued at USD 36.78 Bn in 2025 and is expected to reach USD 85.51 ...

The SEQUOIA arm D study demonstrates promising outcomes for treatment-naive patients with CLL, including high-risk patients.

It’s scary to think that we may have been using a surrogate — BMI — that may not have been all that accurate over the years," ...

In particular, they pointed to ivonescimab’s progression-free survival hazard ratio of 0.52 when paired with chemo. That ...

According to a new study in Haemophilia, up to 60% of patients with severe HA have no known family history, making early ...

During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

JAK inhibitors commonly induce acne in IBD patients, with upadacitinib posing the highest risk. Middle-aged adults and those ...

Global Enzyme Inhibitors Market is valued approximately at USD 180.38 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 3.53% over the forecast period 2024-2032. Read ...